专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2017158367A1 PEPTIDES 审中-公开
标题翻译：肽
公开(公告)号：WO2017158367A1
公开(公告)日：2017-09-21
申请号：PCT/GB2017/050732
申请日：2017-03-16
申请人： IMMUNOCORE LIMITED , ADAPTIMMUNE LIMITED
发明人： POWLESLAND, Alex , BOMBIK, Izabela , MAI, Nicole , SAYER, Christopher
IPC分类号： C07K4/12 , A61K39/00
CPC分类号： A61K39/0011 , A61K2039/605 , C07K14/4748 , C07K14/7051 , C12N15/62 , G01N33/5011 , G01N2500/10
摘要： The present invention relates to novel peptides derived from Progesterone-associated endometrial protein (PAEP), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.
摘要翻译：本发明涉及源自孕酮相关子宫内膜蛋白（PAEP）的新型肽，包含与重组MHC分子结合的此类肽的复合物，以及呈递与MHC分子复合的所述肽的细胞。本发明还提供了结合本发明的肽和/或复合物的结合部分。这样的部分可用于开发用于治疗诸如癌症的疾病的免疫治疗剂。

2. 发明申请

WO2017147139A1 NEOANTIGEN COMPOSITIONS AND METHODS OF USING THE SAME IN IMMUNOONCOTHERAPY 审中-公开
标题翻译： NEONANGEN组合物及其在免疫治疗中使用的组合物和方法
公开(公告)号：WO2017147139A1
公开(公告)日：2017-08-31
申请号：PCT/US2017/018855
申请日：2017-02-22
申请人： OCEANSIDE BIOTECHNOLOGY
发明人： ETHELL, Douglas, Wayne
IPC分类号： A61K39/00 , C07K14/47 , C12N15/12
CPC分类号： C07K14/70539 , A61K39/0011 , A61K2039/5154 , A61K2039/5158 , A61K2039/53 , A61K2039/605 , C07K14/47 , C07K2319/40
摘要： Provided herein are, inter alia, compositions including a fusion protein containing an antigenic cancer peptide and a mature MHC class II peptide, a nucleic acid encoding the protein, a pharmaceutical formulation thereof, an antigen-presenting cell expressing the protein. Also provided herein are methods for treating cancer utilizing these compositions.
摘要翻译：本文提供的组合物尤其包括含有抗原癌肽和成熟MHC II类肽的融合蛋白，编码该蛋白的核酸，其药物制剂，抗原呈递细胞表达蛋白质。本文还提供了利用这些组合物治疗癌症的方法。

3. 发明申请

WO2017089786A1 PEPTIDES 审中-公开
标题翻译：肽
公开(公告)号：WO2017089786A1
公开(公告)日：2017-06-01
申请号：PCT/GB2016/053668
申请日：2016-11-23
申请人： IMMUNOCORE LIMITED , ADAPTIMMUNE LIMITED
发明人： POWLESLAND, Alex
IPC分类号： C07K14/47 , C07K14/12
CPC分类号： C07K14/4748 , A61K39/0011 , A61K2039/605
摘要： The present invention relates to novel peptides derived from Centrosomal protein C10orf90 (C10orf90) as well as from other proteins, complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.
摘要翻译：本发明涉及源自中心体蛋白质C10orf90（C10orf90）以及来自其它蛋白质的新肽，包含与重组MHC分子结合的此类肽的复合物，以及呈递与MHC分子复合的所述肽的细胞。本发明还提供了结合本发明的肽和/或复合物的结合部分。这样的部分可用于开发用于治疗诸如癌症的疾病的免疫治疗剂。

4. 发明申请

WO2011092675A3 MOLECULAR COMPLEX FOR TARGETING ANTIGENS TOWARDS CELLS COMPRISING ANTIGENS AND USES THEREOF FOR VACCINATION 审中-公开
标题翻译：用于靶向包含抗原的细胞的抗原的分子复合物及其用于疫苗的用途
公开(公告)号：WO2011092675A3
公开(公告)日：2015-07-09
申请号：PCT/IB2011050437
申请日：2011-02-01
申请人： COMMISSARIAT ENERGIE ATOMIQUE , LEONETTI MICHEL , SAVATIER ALEXANDRA , GADZINSKI ADELINE , BOULAIN JEAN-CLAUDE
发明人： LEONETTI MICHEL , SAVATIER ALEXANDRA , GADZINSKI ADELINE , BOULAIN JEAN-CLAUDE
IPC分类号： A61K39/385 , A61K47/48 , A61P31/00 , A61P35/00 , C07K14/16 , C07K16/28 , C07K16/42 , C12N15/63
CPC分类号： C07K16/18 , A61K39/39 , A61K47/64 , A61K47/6415 , A61K47/6811 , A61K2039/605 , C07K16/2833
摘要： The invention relates to a molecular complex for targeting the antigen towards cells comprising antigens, including at least one antigen associated with at least two ligands of surface molecules of cells comprising antigens, said complex including at least one first ligand of a sulphated sugar of the glycosaminoglycan family and a second ligand of a specific surface molecule of cells comprising antigens, and said first ligand being covalently bonded with said antigen and/or said second ligand.
摘要翻译：本发明涉及用于将抗原靶向包含抗原的细胞的分子复合物，所述抗原包括至少一种与包含抗原的细胞的表面分子的至少两个配体相关的抗原，所述复合物包括糖胺聚糖的硫酸化糖的至少一种第一配体家族和包含抗原的细胞的特异性表面分子的第二配体，并且所述第一配体与所述抗原和/或所述第二配体共价键合。

5. 发明申请

WO2014209868A1 COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY 审中-公开
标题翻译：免疫组织和方法
公开(公告)号：WO2014209868A1
公开(公告)日：2014-12-31
申请号：PCT/US2014/043629
申请日：2014-06-23
申请人： NEXIMMUNE
发明人： MCCREEDY, Bruce , JONES, Timothy David , CARR, Francis Joseph
IPC分类号： A61K39/00
CPC分类号： A61K47/48915 , A61K38/1774 , A61K39/0011 , A61K39/39 , A61K39/3955 , A61K39/44 , A61K47/6937 , A61K2039/505 , A61K2039/605 , A61K2039/6093 , C07K14/70539 , C07K16/2818 , C07K16/465 , C07K2317/20 , C07K2317/24 , C07K2317/52 , C07K2317/565 , C07K2317/75 , C07K2317/94 , C07K2319/30 , C12N9/0071 , C12Y114/18001
摘要： The present invention provides compositions and methods for immunotherapy, which include shelf-stable pharmaceutical compositions for inducing antigen-specific T cells. Such compositions are employed as components of an artificial antigen presenting cell (aAPC), to provide a patient with complexes for presentation of an antigen (e.g., a tumor antigen) and/or a T cell co-stimulatory molecule.
摘要翻译：本发明提供用于免疫治疗的组合物和方法，其包括用于诱导抗原特异性T细胞的储存稳定的药物组合物。使用这样的组合物作为人造抗原呈递细胞（aAPC）的组分，为患者提供用于呈递抗原（例如肿瘤抗原）和/或T细胞共刺激分子的复合物。

6. 发明申请

WO2012044999A2 REVERSIBLE PROTEIN MULTIMERS, METHODS FOR THEIR PRODUCTION AND USE 审中-公开
标题翻译：可逆蛋白多体，其生产和使用方法
公开(公告)号：WO2012044999A2
公开(公告)日：2012-04-05
申请号：PCT/US2011/054335
申请日：2011-09-30
申请人： LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. , LUESCHER, Immanuel, F. , SCHMIDT, Julien , GUILLAUME, Philippe , DOJCINOVIC, Danijel
发明人： LUESCHER, Immanuel, F. , SCHMIDT, Julien , GUILLAUME, Philippe , DOJCINOVIC, Danijel
IPC分类号： A61K39/385
CPC分类号： C07K17/00 , A61K39/00 , A61K39/385 , A61K2039/605 , A61K2039/627 , A61K2039/64 , C07K14/70539
摘要： Some aspects of this invention are based on the recognition that reversible protein multimers in which monomeric proteins are conjugated to a carrier molecule via chelation complex bonds are stable under physiological conditions and can be dissociated in a controlled manner under physiological, nontoxic conditions. Accordingly, such protein multimers are useful for a variety of in vitro, ex vivo, and in vivo application for research, diagnostics, and therapy. Some aspect of this invention provide reversible MHC protein multimers, and methods of using such multimers in the detection and/or isolation of specific T-cells or T-cell populations. Because reversible MHC multimers can efficiently be dissociated, the time of MHC binding to T-cell receptors, and, thus, T-cell receptor- mediated T-cell activation can be minimized. The use of reversible MHC multimers as provided herein, accordingly, allows for the detection and isolation of bona fide antigen- specific CD8+ T cells without inducing activation dependent cell death, including rare, therapeutically valuable T- cells expressing T-cell receptors binding tumor antigens with high affinity. Methods for the production and use of reversible multimers are also provided.
摘要翻译：本发明的一些方面基于以下认识：其中单体蛋白经由螯合络合物键与载体分子缀合的可逆蛋白多聚体在生理条件下是稳定的，并且可以以受控方式解离生理的，无毒的条件。因此，这样的蛋白质多聚体可用于各种体外，离体和体内应用于研究，诊断和治疗。本发明的一些方面提供了可逆的MHC蛋白质多聚体，以及在检测和/或分离特定的T细胞或T细胞群中使用此类多聚体的方法。因为可逆的MHC多聚体可以有效地解离，所以MHC与T细胞受体结合的时间以及因此T细胞受体介导的T细胞活化的时间可以最小化。因此，本文提供的可逆MHC多聚体的使用允许检测和分离真正的抗原特异性CD8 + T细胞而不诱导活化依赖性细胞死亡，包括表达罕见的治疗上有价值的T细胞表达 T细胞受体以高亲和力结合肿瘤抗原。还提供了生产和使用可逆多聚体的方法。

7. 发明申请

WO2011103465A2 BOTULINUM NEUROTOXIN ANTIGENIC COMPOSITIONS AND METHODS 审中-公开
标题翻译： BOTULINUM神经毒素抗原组合物和方法
公开(公告)号：WO2011103465A2
公开(公告)日：2011-08-25
申请号：PCT/US2011/025482
申请日：2011-02-18
申请人： ZDANOVSKY, Alexey Gennadievich
发明人： ZDANOVSKY, Alexey Gennadievich
IPC分类号： A61K39/08
CPC分类号： A61K39/08 , A61K2039/605
摘要： Methods and compositions pertaining to botulinum neurotoxin (BoNT) light chain epitopes are provided. In particular, the methods and compositions relate to the use of real and mimetic BoNT light chain epitopes for generating an immune response in a subject, and for immunization against BoNT toxicity. Methods and compositions for detecting, isolating, and purifying BoNT epitopes and anti-BoNT antibodies are also provided.
摘要翻译：提供了与肉毒杆菌神经毒素（BoNT）轻链表位相关的方法和组合物。特别地，所述方法和组合物涉及使用真实和模拟的BoNT轻链表位在受试者中产生免疫应答以及针对BoNT毒性的免疫。还提供了用于检测，分离和纯化BoNT表位和抗BoNT抗体的方法和组合物。

8. 发明申请

WO2008054540A9 INDUCING IMMUNE RESPONSES TO INFLUENZA VIRUS USING POLYPEPTIDE AND NUCLEIC ACID COMPOSITIONS 审中-公开
标题翻译：使用多肽和核酸组合物诱导对流感病毒的免疫应答
公开(公告)号：WO2008054540A9
公开(公告)日：2008-07-03
申请号：PCT/US2007011900
申请日：2007-05-18
申请人： PHARMEXA INC , ALEXANDER JEFFERY L , BILSEL PAMUK A , NEWMAN MARK J
发明人： ALEXANDER JEFFERY L , BILSEL PAMUK A , NEWMAN MARK J
IPC分类号： A61K31/70 , A61K38/00 , A61P43/00 , C07H21/04 , C12N5/00 , C12N15/00
CPC分类号： A61K39/145 , A61K39/12 , A61K39/385 , A61K39/39 , A61K2039/53 , A61K2039/545 , A61K2039/55505 , A61K2039/55566 , A61K2039/605 , A61K2039/627 , C07K14/005 , C12N2760/16122 , C12N2760/16134
摘要： The present invention provides polynucleotides and polypeptides capable of enhancing the immune response of a human in need of protection against influenza virus infection by administering in vivo, into a tissue of the human, at least one polynucleotide comprising one or more regions of nucleic acid encoding an influenza protein or a fragment, variant, or derivative thereof, or at least one polypeptide encoded therefrom. The present invention also relates to identifying and preparing influenza virus epitopes and to polynucleotides and polypeptides comprising such influenza virus epitopes. The present invention also relates to compositions and methods of use in the prevention and treatment of influenza virus infection.
摘要翻译：本发明提供能够通过在体内施用人体组织中能够增强需要防止流感病毒感染的人的免疫应答的多核苷酸和多肽，至少一种多核苷酸，其包含一个或多个编码流感蛋白或其片段，变体或衍生物，或至少一种由其编码的多肽。本发明还涉及鉴定和制备流感病毒表位以及包含这种流感病毒表位的多核苷酸和多肽。本发明还涉及用于预防和治疗流感病毒感染的组合物和方法。

9. 发明申请

WO2005103259A1 SARS-COV NUCLEOCAPSID PROTEIN EPITOPES AND USES THEREOF 审中-公开
标题翻译： SARS-COV NUCLEOCAPSID蛋白抗体及其用途
公开(公告)号：WO2005103259A1
公开(公告)日：2005-11-03
申请号：PCT/CA2005/000632
申请日：2005-04-26
申请人： UNIVERSITY HEALTH NETWORK , BECKMAN COULTER, INC. , UNIVERSITE DE MONTREAL , NATIONAL HEALTH RESEARCH INSTITUTES , KELVIN, David , PERSAD, Desmond , CAMERON, Cheryl , BRAY, Kurtis, R. , LOFARO, Lori, R. , JOHNSON, Camille , SEKALY, Rafick-Pierre , YOUNES, Souheil-Antoine , CHONG, Pele
发明人： KELVIN, David , PERSAD, Desmond , CAMERON, Cheryl , BRAY, Kurtis, R. , LOFARO, Lori, R. , JOHNSON, Camille , SEKALY, Rafick-Pierre , YOUNES, Souheil-Antoine , CHONG, Pele
IPC分类号： C12N15/50
CPC分类号： C07K14/005 , A61K2039/53 , A61K2039/605 , A61K2039/622 , C12N2770/20022 , G01N33/56983 , G01N2333/165
摘要： The invention provides polypeptides, nucleic acids, antibodies, compositions, vaccines, microarrays and uses thereof for the prevention, treatment of SARS and SARS-CoV infection. The invention further provides uses of the above-noted products for the detection and diagnosis of SARS and SARS-CoV infection. The invention further provides corresponding methods and commercial packages relating to such uses.
摘要翻译：本发明提供了用于预防，治疗SARS和SARS-CoV感染的多肽，核酸，抗体，组合物，疫苗，微阵列及其用途。本发明还提供了上述产品用于检测和诊断SARS和SARS-CoV感染的用途。本发明还提供了与这种用途有关的相应方法和商业包装。

10. 发明申请

WO0230964A3 COMPARATIVE LIGAND MAPPING FROM MHC POSITIVE CELLS 审中-公开
标题翻译：从MHC阳性细胞的比较配体映射
公开(公告)号：WO0230964A3
公开(公告)日：2003-09-25
申请号：PCT/US0131931
申请日：2001-10-10
申请人： UNIV OKLAHOMA , HICKMAN HEATHER , HILDEBRAND WILLIAM
发明人： HICKMAN HEATHER , HILDEBRAND WILLIAM
IPC分类号： A61K39/39 , C07K14/08 , C07K14/16 , C07K14/47 , C07K14/705 , C07K14/74 , C07K14/78 , C12N9/12 , C12N9/64 , C12N15/09 , C12P21/02 , C12Q1/02 , C12Q1/68 , G01N33/15 , G01N33/50 , G01N33/53 , G01N33/566 , A61K47/42 , C07K14/155 , C12N9/50 , G01N33/569 , G01N33/574
CPC分类号： G01N33/6878 , A61K39/39 , A61K2039/605 , A61K2039/622 , C07K14/005 , C07K14/47 , C07K14/4702 , C07K14/4728 , C07K14/70539 , C07K14/70571 , C07K14/78 , C07K16/2833 , C07K2319/00 , C12N9/1247 , C12N9/6421 , C12N2740/16122 , G01N33/5008 , G01N33/502 , G01N33/5044 , G01N33/5091 , G01N33/569 , G01N33/6824 , G01N33/6848 , G01N2333/16 , G01N2333/70539
摘要： The present invention relates generally to a methodology for the isolation, purification and identification of peptide ligands presented by MHC positive cells. In particular, the methodology of the present invention relates to the isolation, purification and identification of these peptide ligands from soluble class I and class II MHC molecules which may be uninfected, infected, or tumorgenic. The methodology of the present invention broadly allows for these peptide ligands and their comcomittant source proteins thereof to be identified and used as markers for infected versus uninfected cells and/or tumorgenic versus nontumorgenic cells with said identification being useful for marking or targeting a cell for therapeutic treatment or priming the immune response against infected cells.
摘要翻译：本发明一般涉及由MHC阳性细胞提供的肽配体的分离，纯化和鉴定的方法。特别地，本发明的方法涉及从可能未感染，感染或肿瘤的可溶性I类和II类MHC分子中分离，纯化和鉴定这些肽配体。本发明的方法广泛地允许鉴定这些肽配体及其共有的源蛋白，并将其用作感染的与未感染的细胞和/或肿瘤与非肿瘤细胞的标记，所述鉴定可用于标记或靶向用于治疗的细胞治疗或引发针对感染细胞的免疫应答。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式